Maraviroc in Rheumatoid Arthritis

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients.

Clinical Trial Description

Following a planned interim analysis in the POC component on 21 August 2008 by the internal DMC (Data Monitoring Committee) of study A4001056, the trial was discontinued due to lack of efficacy. All participating investigators/country offices and monitors were notified on 22 August 2008 to cease patient enrollment. The DMC indicated that maraviroc was well tolerated in the Rheumatoid Arthritis patients and there were no safety concerns in the study. The termination date of this trial was 07 October 2008 when the last patient last visit occurred. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00427934
Study type	Interventional
Source	Pfizer
Contact
Status	Terminated
Phase	Phase 2
Start date	February 2007
Completion date	October 2008

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01682512` - Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis	Phase 3
Completed	`NCT00539760` - A Phase I Rheumatoid Arthritis Study in Healthy Volunteers	Phase 1
Active, not recruiting	`NCT03312465` - Anatomical Shoulder Domelock System Study
Completed	`NCT01208181` - A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)	Phase 3
Completed	`NCT03254810` - Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects	Phase 1
Completed	`NCT01711814` - A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study	Phase 2
Completed	`NCT03315494` - Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers	Phase 1
Withdrawn	`NCT03241446` - Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)	Phase 1
Completed	`NCT02748785` - MTX Discontinuation and Vaccine Response	Phase 4
Completed	`NCT02553018` - Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe	Phase 3
Active, not recruiting	`NCT02260778` - Treat-to-target in RA: Collaboration To Improve adOption and adhereNce	N/A
Completed	`NCT02569736` - Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
Completed	`NCT01750931` - This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.	Phase 2
Withdrawn	`NCT01204138` - Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA	Phase 2
Not yet recruiting	`NCT01154647` - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes	N/A
Completed	`NCT00913458` - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis	Phase 4
Completed	`NCT00973479` - An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy	Phase 3
Completed	`NCT00975130` - Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)	Phase 3
Completed	`NCT00660647` - Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)	Phase 3
Completed	`NCT00550446` - A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis	Phase 2